C3 Glomerulopathy With Concurrent Thrombotic Microangiopathy: Clinical and Immunological Features.
Fiche publication
Date publication
avril 2023
Journal
American journal of kidney diseases : the official journal of the National Kidney Foundation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUCLOUX Didier
Tous les auteurs :
Chabannes M, Rabant M, El Sissy C, Dragon-Durey MA, Vieira Martins P, Meuleman MS, Karras A, Buob D, Bridoux F, Daugas E, Audard V, Caillard S, Olagne J, Kandel C, Ferlicot S, Philipponnet C, Crepin T, Thervet E, Ducloux D, Frémeaux-Bacchi V, Chauvet S
Lien Pubmed
Résumé
C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are two distinct rare kidney diseases caused by dysregulation of the alternative complement pathway. Patients with C3G and concurrent kidney lesions of thrombotic microangiopathy (TMA) have been rarely reported. The objectives of this study were to characterize the clinical features and underlying immunological abnormalities in these patients.
Mots clés
C3 glomerulopathy, complement alternative pathway, eculizumab, monoclonal gammopathy, thrombotic microangiopathy
Référence
Am J Kidney Dis. 2023 04 13;: